Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M

July 4, 2019 updated by: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Clinical Study on the Safety and Efficacy of Medium-chain Fatty Acid Capsules (CNT-02) for Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Neutral Lipid Storage Disease With Myopathy (NLSD-M)

This study is planning to evaluate the safety and clinical efficacy of medium-chain fatty acid capsules (food-grade CNT-02) in subjects with primary triglyceride deposit cardiomyovasculopathy (TGCV) and neutral lipid storage disease with myopathy (NLSD-M) associated with adipose triglyceride lipase (ATGL) genetic defects.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
2

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
    • Lazio
      • Rome, Lazio, Italy, 00163
        • IRCCS San Raffaele
      • Rome, Lazio, Italy, 00193
        • San Filippo Neri Hospital
    • Lombardia
      • Milano, Lombardia, Italy, 20123
        • Catholic University
    • Venice
      • Lido, Venice, Italy, 30126
        • Fondazione Ospedale San Camillo IRCCS
  • Japan
    • Aomori-prefecture
      • Aomori-city, Aomori-prefecture, Japan, 030-8553
        • Aomori Prefectural Chuo Hospital
    • Miyagi-prefecture
      • Sendai-city, Miyagi-prefecture, Japan, 980-8575
        • Tohoku University
    • Osaka-prefecture
      • Suita-city, Osaka-prefecture, Japan, 565-0874
        • Graduate School of Osaka University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients for whom ATGL gene deletion has been previously confirmed.
  2. Patients who can take the investigational product orally.
  3. Male and female who are at least 20 years old at the time of consent.
  4. Patients who gave written informed consent.

Exclusion Criteria:

  1. Patients with diabetic ketoacidosis.
  2. Patients with the possibility of diabetic ketoacidosis (patients with poorly controlled diabetes mellitus [HbA1c>8.4%, NGSP])
  3. Patients with terminal malignancy.
  4. Pregnant or lactating women.
  5. Patients who do not consent to using contraception while participating in this study.
  6. Patients allergic to MCT oil.
  7. Patients participating in other clinical trial.
  8. Otherwise, patients determined to be ineligible for this study by the investigator or sub-investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Medium-chain Fatty Acid (CNT-02)
Dietary supplement: CNT-02
Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
The maximum walking distance in a 6-minute walk test at 3 months
Time Frame: 3 months
Measuring maximum walking distance of 6-minute walk test. Calculating variation of those measured values from baseline to 3 months.
3 months
The maximum walking distance in a 6-minute walk test at 6 months
Time Frame: 6 months
Measuring maximum walking distance of 6-minute walk test . Calculating variation of those measured values from baseline to 6 months.
6 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
MRC sum score in manual muscle testing (MMT) at 3 months
Time Frame: 3 months
Evaluating muscle strength by manual muscle test used MRC score. Assessing change from baseline to 3 months.
3 months
MRC sum score in manual muscle testing (MMT) at 6 months
Time Frame: 6 months
Evaluating muscle strength by manual muscle test used MRC score. Assessing change from baseline to 6 months.
6 months
Fractions of lung volume such as % vital capacity, measured by spirometer at 3 months
Time Frame: 3 months
Evaluating the respiratory functions by % Vital capacity measured by spirometer. Assessing change from baseline to 3 months.
3 months
Fractions of lung volume such as % vital capacity, measured by spirometer at 6 months
Time Frame: 6 months
Evaluating the respiratory functions by % Vital capacity measured by spirometer. Assessing change from baseline to 6 months.
6 months
The amount of fat measured by computed tomography (CT) of the skeletal muscle (fat deposition) at 3 months
Time Frame: 3 months
Evaluating fat deposition in the skeletal muscle by CT. Assessing change from baseline to 3 months.
3 months
The amount of fat measured by computed tomography (CT) of the skeletal muscle (fat deposition) at 6 months
Time Frame: 6 months
Evaluating fat deposition in the skeletal muscle by CT. Assessing change from baseline to 6 months.
6 months
Parameters of cardiac function, such as the left ventricular ejection fraction by echocardiography at 3 months
Time Frame: 3 months
Evaluating cardiac function using Left ventricular ejection fraction etc. by echocardiography. Assessing change from baseline to 3 months.
3 months
Parameters of cardiac function, such as the left ventricular ejection fraction by echocardiography at 6 months
Time Frame: 6 months
Evaluating cardiac function using Left ventricular ejection fraction etc. by echocardiography. Assessing change from baseline to 6 months.
6 months
Serum free fatty acid levels at 3 months
Time Frame: 3 months
Analysing concentration of fatty acids in serum using HPLC method. Assessing change from baseline to 3 months.
3 months
Serum free fatty acid levels at 6 months
Time Frame: 6 months
Analysing concentration of fatty acids in serum using HPLC method. Assessing change from baseline to 6 months.
6 months

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Incidence, severity, seriousness, causality, and outcomes of adverse events
Time Frame: 6 months
A frequency counting of the adverse events. LLT code will be assigned to the reported adverse event using the MedDRA dictionary.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Kenichi Hirano, MD, Ph.D, Department of Cardiovascular Medicine, Faculty of Internal Medicine, Graduate School of Osaka University, Japan
  • Principal Investigator: Elena M Pennisi, MD, Ph.D, Department of Neurology, San Filippo Neri Hospital, Rome, Italy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 5, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2019

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 6, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 8, 2016

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 13, 2016

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 8, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 4, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TRICVD1527
  • UMIN000023043 (Other Identifier: UMIN-CTR)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings